Libo Sun

机构：Omron (Japan), Geron (United States), Gilead Sciences (United States)

发表论文 53 篇 · 总被引 945 次 · h-index 10

代表论文

• Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial (2023 · The Lancet · 被引 137)
• Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science (2024 · Clinical and Translational Science · 被引 31)
• Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor (2024 · CPT Pharmacometrics & Systems Pharmacology · 被引 6)
• Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study (2024 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 4)
• Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis (2025 · Clinical and Translational Science · 被引 3)
• Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study (2023 · Blood · 被引 3)